Trevi Therapeutics

Company snapshot

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statisti

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Trevi Therapeutics. Not investment advice.

• Peer + 0 momentum

  Shanghai Zerun Biotechnology

  TA overlap score 22.2

• Peer + 0 momentum

  Contineum Therapeutics

  TA overlap score 21.4

Recent activity

Latest pipeline, patent, and corporate events for Trevi Therapeutics.

1. Jun 8, 2026 Clinical update

   NAL03-202 — Phase 2

2. Jun 8, 2026 Clinical update

   Nalbuphine HCl solution — Phase 1

3. Jun 8, 2026 Clinical update

   nalbuphine HCl ER tablets 90 mg BID — Phase 3

4. Jun 8, 2026 Clinical update

   nalbuphine HCl ER tablets 60 mg BID — Phase 3

5. Jun 8, 2026 Clinical update

   Nalbuphine ER Tablets — Phase 3

View all clinical trial activity →

• What is Trevi Therapeutics?

  Trevi Therapeutics is a pharma organization headquartered in New Haven, USA. It trades on NYSE under ticker TRVI. Primary therapeutic focus areas include Prurigo Nodularis, Uremic Pruritus, Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Refractory Chronic Cou

• Is Trevi Therapeutics publicly traded?

  Yes. Trevi Therapeutics is listed with ticker TRVI on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Trevi Therapeutics develop or market?

  We link 8 drug profile(s) where Trevi Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/trevi-therapeutics#company-drugs.

• What are the latest developments for Trevi Therapeutics?

  In the last 12 months our linked public records show 11 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Trevi Therapeutics focus on?

  Trevi Therapeutics focuses on Prurigo Nodularis, Uremic Pruritus, Idiopathic Pulmonary Fibrosis (IPF) based on our analysis of their pipeline programs and drug development activities.